Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
News for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) centers on its role as a commercial-stage medical dermatology and biopharmaceutical company focused on immune-mediated skin diseases. Company announcements frequently highlight developments in its ZORYVE (roflumilast) topical franchise for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis, along with updates on its broader immuno-dermatology pipeline.
Investors and clinicians following ARQT news can expect detailed coverage of regulatory milestones, such as U.S. Food and Drug Administration (FDA) approvals and supplemental new drug application (sNDA) acceptances for new age groups and indications. Releases describe label expansions for ZORYVE cream and foam, including approvals for pediatric atopic dermatitis and seborrheic dermatitis, and FDA review timelines for potential new pediatric plaque psoriasis indications.
Arcutis also reports on clinical trial progress and data presentations. Recent news includes completion of enrollment in pediatric studies like INTEGUMENT-INFANT, publication of long-term safety and efficacy data for ZORYVE foam 0.3% in seborrheic dermatitis, and new Phase 3 analyses showing improvements in itch, sleep disruption, and long-term disease control with ZORYVE cream 0.15% and 0.05% in atopic dermatitis.
Financial and corporate updates form another key news category. The company issues quarterly earnings releases detailing net product revenue for ZORYVE, outlines strategies for sustainable growth, and provides guidance on future net product sales. Additional items include inducement equity grants, participation in investor conferences, and board-level changes disclosed via press releases and Form 8-K filings.
News flow also covers pipeline and strategic priorities, such as Phase 2 proof-of-concept trials of ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, and early clinical development plans for ARQ-234, a CD200 receptor checkpoint agonist being developed as a potential biologic for atopic dermatitis. Together, these updates give readers insight into Arcutis’ commercial performance, regulatory trajectory, and ongoing research in immuno-dermatology.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported strong Q2 2025 financial results, with net product revenue of $81.5 million, representing a 164% year-over-year increase and 28% sequential growth. The quarter was marked by significant achievements, including FDA approval of ZORYVE foam 0.3% for plaque psoriasis treatment and the initiation of the INTEGUMENT-INFANT study for ZORYVE cream in infants with atopic dermatitis.
Key financial metrics include reduced net loss of $15.9 million ($0.13 per share) compared to $52.3 million in Q2 2024, with cash reserves of $191.1 million. The company's ZORYVE portfolio showed strong performance across all formulations, with over 1 million total prescriptions dispensed to date. Additionally, Arcutis submitted an IND for ARQ-234, a novel fusion protein for atopic dermatitis treatment.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has scheduled its second quarter 2025 financial results announcement for August 6, 2025 after market close.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation materials through the "Events" section of Arcutis' website, with an archived replay available afterward on their investor website.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the granting of 14,000 restricted stock units to two new employees. The grants were approved by the company's Compensation Committee under the 2022 Inducement Plan, effective July 1, 2025.
The restricted stock units have a four-year vesting schedule, with 25% vesting annually, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced that its product ZORYVE® (roflumilast) cream 0.15% has received a strong recommendation in the American Academy of Dermatology's (AAD) updated guidelines for adult atopic dermatitis management. ZORYVE is the first FDA-approved branded topical PDE4 inhibitor for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis.
Among newly evaluated branded topical therapies, ZORYVE stands out as the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis. The recommendation highlights the drug's efficacy in improving pruritus and disease severity, favorable tolerability, and low discontinuation rates. The treatment targets a condition affecting over 16 million adults in the United States.
Arcutis Biotherapeutics (NASDAQ: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, June 10, 2025, at 4:00 pm EDT. The event will be accessible via webcast in the "Events" section of Arcutis' website, with the replay remaining available for 180 days after the conference.